- Home
- INSM vs JKHY Comparison
INSM vs JKHY Comparison
Compare INSM & JKHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- JKHY
- Stock Information
- Founded
- INSM 1988
- JKHY 1976
- Country
- INSM United States
- JKHY United States
- Employees
- INSM N/A
- JKHY N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- JKHY Retail: Computer Software & Peripheral Equipment
- Sector
- INSM Health Care
- JKHY Technology
- Exchange
- INSM Nasdaq
- JKHY Nasdaq
- Market Cap
- INSM 12.5B
- JKHY 13.4B
- IPO Year
- INSM 2000
- JKHY N/A
- Fundamental
- Price
- INSM $71.86
- JKHY $172.76
- Analyst Decision
- INSM Strong Buy
- JKHY Buy
- Analyst Count
- INSM 16
- JKHY 12
- Target Price
- INSM $83.64
- JKHY $188.73
- AVG Volume (30 Days)
- INSM 1.6M
- JKHY 605.1K
- Earning Date
- INSM 10-31-2024
- JKHY 11-05-2024
- Dividend Yield
- INSM N/A
- JKHY 1.29%
- EPS Growth
- INSM N/A
- JKHY 10.52
- EPS
- INSM N/A
- JKHY 5.47
- Revenue
- INSM $342,958,000.00
- JKHY $2,245,157,000.00
- Revenue This Year
- INSM $18.96
- JKHY $9.18
- Revenue Next Year
- INSM $41.96
- JKHY $7.28
- P/E Ratio
- INSM N/A
- JKHY $31.21
- Revenue Growth
- INSM 22.13
- JKHY 5.91
- 52 Week Low
- INSM $21.92
- JKHY $151.93
- 52 Week High
- INSM $80.53
- JKHY $189.63
- Technical
- Relative Strength Index (RSI)
- INSM 51.18
- JKHY 29.88
- Support Level
- INSM $64.86
- JKHY $169.61
- Resistance Level
- INSM $73.95
- JKHY $177.69
- Average True Range (ATR)
- INSM 2.98
- JKHY 3.44
- MACD
- INSM 0.26
- JKHY -1.12
- Stochastic Oscillator
- INSM 72.73
- JKHY 8.29
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
About JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing for us banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.